2. Immunology/Inflammation NF-κB Metabolic Enzyme/Protease Apoptosis
  3. Reactive Oxygen Species (ROS) Apoptosis Ferroptosis
  4. anti-TNBC agent-15

anti-TNBC agent-15 is a platinum (IV) complex with anti-triple-negative breast cancer activity. anti-TNBC agent-15 inhibits cancer cell viability. anti-TNBC agent-15 reverses the resistance of triple-negative breast cancer cells to Cisplatin (HY-17394), increases intracellular uptake, and effectively triggers apoptosis by inducing DNA damage, enhancing intracellular ROS accumulation and activating the mitochondrial pathway. anti-TNBC agent-15 enhances lipid peroxidation, interferes with the signal transduction of the cystine/glutamate transporter-glutathione peroxidase axis, and induces ferroptosis. anti-TNBC agent-15 significantly inhibits tumor growth in triple-negative breast cancer/Cisplatin xenograft models. anti-TNBC agent-15 can be used for the research of triple-negative breast cancer.

Para uso exclusivo en investigación. No vendemos a pacientes.

anti-TNBC agent-15

anti-TNBC agent-15 Estructura química

Tamaño Stock
50 mg   Obtener un presupuesto  
100 mg   Obtener un presupuesto  
250 mg   Obtener un presupuesto  

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

anti-TNBC agent-15 Related Antibodies

Top Publications Citing Use of Products

  • Actividad biológica

  • Pureza y Documentación

  • Referencias

  • Revisión del cliente

Descripciòn

anti-TNBC agent-15 is a platinum (IV) complex with anti-triple-negative breast cancer activity. anti-TNBC agent-15 inhibits cancer cell viability. anti-TNBC agent-15 reverses the resistance of triple-negative breast cancer cells to Cisplatin (HY-17394), increases intracellular uptake, and effectively triggers apoptosis by inducing DNA damage, enhancing intracellular ROS accumulation and activating the mitochondrial pathway. anti-TNBC agent-15 enhances lipid peroxidation, interferes with the signal transduction of the cystine/glutamate transporter-glutathione peroxidase axis, and induces ferroptosis. anti-TNBC agent-15 significantly inhibits tumor growth in triple-negative breast cancer/Cisplatin xenograft models. anti-TNBC agent-15 can be used for the research of triple-negative breast cancer[1].

In Vitro

anti-TNBC agent-15 (Compound 14) (100 nM-50 μM; 72 h) potently inhibits MDA-MB-231, A549, HCT-116, A549/CDDP, MDA-MB-231/CDDP and MCF-10 A cells, with IC50 values of 2.38, 3.77, 4.36, 4.29, 2.25 and 12.17, respectively[1].
anti-TNBC agent-15 (5 μM; 12-24 h) significantly increases intracellular platinum accumulation in MDA-MB-231 cells and cisplatin-resistant MDA-MB-231/CDDP cells, potently induces DNA damage in MDA-MB-231/CDDP cells, and elevates the expression levels of γ-H2AX and p53 as well as the olive tail moment value in the comet assay[1].
anti-TNBC agent-15 (5 μM; 24 h) induces apoptosis in Cisplatin-resistant MDA-MB-231/CDDP cells by upregulating pro-apoptotic proteins and downregulating the anti-apoptotic protein Bcl-2, and disrupts the mitochondrial membrane potential of the cells[1].
anti-TNBC agent-15 (5 μM; 24 h) inhibits the cystine/glutamate transporter-glutathione peroxidase axis in Cisplatin-resistant MDA-MB-231/CDDP cells by downregulating the expression of xCT and GPX4[1].
anti-TNBC agent-15 (5 μM; 24-72 h) induces cell death in cisplatin-resistant MDA-MB-231/CDDP cells via ferroptosis[1].
anti-TNBC agent-15 (5 μM; 12-24 h) disrupts the GSH redox system and induces extensive lipid peroxidation in Cisplatin-resistant MDA-MB-231/CDDP cells[1].
anti-TNBC agent-15 (5 μM; 24 h) inhibits migration and invasion of cisplatin-resistant MDA-MB-231/CDDP cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

anti-TNBC agent-15 Related Antibodies

Cell Viability Assay[1]

Cell Line: MDA-MB-231, A549, HCT-116, A549/CDDP, MDA-MB-231/CDDP, MCF-10 A cells
Concentration: 100 nM, 500 nM, 1 μM, 5 μM, 10 μM, 50
μM
Incubation Time: 72 h
Result: Exhibited the highest cytotoxicity across all tested cell lines, with IC50 values of 2.38 μM (MDA-MB-231), 3.77 μM (A549), 4.36 μM (HCT-116), 4.29 μM (A549/CDDP), 2.25 μM (MDA-MB-231/CDDP), and 12.17 μM (MCF-10 A).
Showed a resistance factor (RF1) of 1.14 (A549/CDDP vs A549) and RF2 of 0.95 (MDA-MB-231/CDDP vs MDA-MB-231), and a selectivity factor (SF) of 5.11 (MCF-10 A vs MDA-MB-231).

Apoptosis Analysis[1]

Cell Line: MDA-MB-231/CDDP cells
Concentration: 5 μM
Incubation Time: 24 h
Result: Induced an apoptotic rate of 52.87% in MDA-MB-231/CDDP cells, which was higher than the rates induced by ligand 8 (22.95%), oxaliplatin (38.4%), and the combination of ligand 8 and oxaliplatin (46.23%).

Western Blot Analysis[1]

Cell Line: MDA-MB-231/CDDP cells
Concentration: 5 μM
Incubation Time: 24 h
Result: Upregulated the expression of pro-apoptotic proteins Cyt c, Bax, cleaved caspase 3, and cleaved caspase 9, with protein densities relative to β-actin reaching ~0.5, ~0.75, ~0.85, and ~0.7, respectively.
Downregulated the expression of anti-apoptotic protein Bcl-2, with a protein density relative to β-actin of ~0.05.\nSignificantly downregulated the expression of cystine/glutamate transporter (xCT) and glutathione peroxidase 4 (GPX4) proteins, with protein densities relative to β-actin reaching ~0.3 and ~0.1, respectively.

Cell Migration Assay [1]

Cell Line: MDA-MB-231/CDDP cells
Concentration: 5 μM
Incubation Time: 24 h
Result: Inhibited the migration and invasion of Cisplatin-resistant MDA-MB-231/CDDP cells
In Vivo

anti-TNBC agent-15 (compound 14) (5.0-16.7 mg/kg; i.v.; every 7 days; 28 days) dose-dependently suppresses cisplatin-resistant triple-negative breast cancer tumor growth in xenograft mice, with a 63.4% TGI rate at the 16.7 mg/kg dose and minimal systemic toxicity[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c-nude (female)[1]
Dosage: 5.0 mg/kg; 16.7 mg/kg
Administration: i.v.; every 7 days; 28 days
Result: Achieved a tumor growth inhibition (TGI) rate of 44.6% at 5.0 mg/kg.
Achieved a tumor growth inhibition (TGI) rate of 63.4% at 16.7 mg/kg.
Showed no significant body weight differences compared to saline control during 28-day treatment, indicating low systemic toxicity.
Induced extensive cell nuclear loss in tumors (16.7 mg/kg dose group, H&E staining).
Demonstrated reduced proliferative activity in tumors (16.7 mg/kg dose group, Ki-67 staining).
Peso molecular

1002.31

Fòrmula

C34H39ClN6O13PtS
SMILES

O=C(O[Pt](OC1=O)([NH2][C@H]2[C@H]3CCCC2)([NH2]3)(Cl)OC1=O)CCCC(OCCOC4=CC=C(/N=N/C5=CC=C(S(=O)(NC6=NC=CC=C6)=O)C=C5)C=C4C(OC)=O)=O
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

anti-TNBC agent-15 Related Classifications

  • Calculadora de molaridad

  • Calculadora de dilución

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

anti-TNBC agent-15Reactive Oxygen Species (ROS)ApoptosisFerroptosisanti-TNBC agentapoptosisferroptosisMDA-MB-231 cellsA549 cellsHCT-116 cellsA549/CDDP cellsMDA-MB-231/CDDP cellsMCF-10 A cellstriple-negative breast cancerBALB/c-nude miceInhibitorinhibitorinhibit

Productos vistos recientemente:

Consulta en línea

Your information is safe with us. * Required Fields.

Nombre del producto

  

Requested Quantity *

Nombre del solicitante *

 

Saludo

Direcciòn del E-mail *

 

Número de teléfono *

Department

 

Nombre de la Organizaciòn *

City

Provincia

Country or Region *

      

Observaciones

Consulta para venta a granel

Inquiry Information

Nombre del producto:
anti-TNBC agent-15
Cat. No.:
HY-182067
Cantidad:
MCE Japan Authorized Agent:

Revisión del cliente

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Nombre del producto

  

Lot #

Nombre del solicitante *

 

Direcciòn del E-mail *

Número de teléfono

 

Department *

Nombre de la Organizaciòn *

 

Country or Region *

Observaciones

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.